PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
18.78%
Revenue growth of 18.78% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
49.59%
Gross profit growth of 49.59% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
190.40%
EBIT growth of 190.40% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
190.40%
Operating income growth of 190.40% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
171.27%
Net income growth of 171.27% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
162.90%
EPS growth exceeding 1.5x Healthcare median of 3.45%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
162.90%
Diluted EPS growth exceeding 1.5x Healthcare median of 3.69%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
2.26%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.43%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-28.58%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-32.85%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
1211.10%
5Y CAGR of 1211.10% while Healthcare is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
736.04%
3Y CAGR of 736.04% while Healthcare median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
-600.11%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-3629.51%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-19942.46%
Negative 3Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
175.53%
Net income/share CAGR of 175.53% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
37300.27%
Net income/share CAGR of 37300.27% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
-73.74%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
4319.20%
Equity/share CAGR of 4319.20% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
1522.06%
5Y equity/share CAGR of 1522.06% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
48.90%
3Y equity/share CAGR of 48.90% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
AR growth of 0.05% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
47.19%
Inventory growth of 47.19% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
3.70%
Asset growth of 3.70% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
3.02%
BV/share growth of 3.02% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-4.80%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
4.80%
R&D growth of 4.80% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
0.20%
SG&A dropping significantly vs. Healthcare median. Joel Greenblatt sees near-term margin upside but checks for underinvestment risk.